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1. Introduction 
Gliomas represent a formidable challenge in terms of pathophysiologic and clinical 
behaviour. 
The frequently used term “glioma” applies to neoplasms derived from components of 
neuroglia: astrocytes, oligodendrocytes and ependima cells with the corrisponding tumors, 
astrocytomas, oligodendrogliomas and ependymomas (Louis et al 2007, Graham et al 2006). 
They represent the most common primary intra-axial brain tumor (40% of intracranial tumors 
with an estimated incidence of 12.000 new cases /year in the U.S.). Importantly, when 
discussing gliomas, the terms benign and malign have little meaning; the WHO classification 
provides a grading system to subdivide gliomas. Grading is based on cellularity, presence of 
giant cells, anaplasia, mitotic activity, microvascular proliferation with or without endothelial 
proliferation, necrosis and pseudopalisading. Astrocytomas and oligodendrogliomas are 
usually defined as grade II (III in the anaplastic form) while glioblastomas are grade IV. So a 
simpler classification describes these tumors as being of low or high grade. 
From a clinical point of view the grading system has an inverse correlation to patient 
survival and it is important in taking decisions as to the therapeutic strategies. 
With the exception of one or two entities (e.g. pilocytic astrocytoma-grade I), a low grade 
glioma will continue to acquire genetic mutations and eventually will transform into a high 
grade neoplasm. This process is defined dedifferentiation and represents the major cause of 
morbidity with low-grade astrocytomas. Genetic markers that correlate with a higher degree 
of malignant degeneration include loss of heterozygosity at chromosomes 10 & 17, alteration 
in tumor suppressor genes 9p, 13q, 19q & 22q, changes in epidermal growth factor receptor 
(EGRF) and platelet derived growth factor (PDGF) and mutation of the p53 suppressor gene. 
To underline the importance of this behaviour, the gliomas that developed in the adult are 
frequently defined as “diffuse” because of  their ability to profoundly infiltrate the brain 
parenchyma (Louis et al 2007).  
Glioblastomas (the most malignant form of glial tumors) are characterized by extensive 
dissemination of tumor cells within the brain that are hallmarked histologically by the 
presence of vascular endothelial proliferation and wide areas of necrosis often presenting 
hemorrhagic components. Besides invasion, enhanced proliferation, angiogenesis and 
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resistance to apoptosis are all involved in the progression and maintenance of this 
malignancy. 
As mentioned above gliomas still represent a formidable clinical challenge. In spite of 
optimal and multidisciplinary treatment (in high grade forms, surgery followed by 
chemotherapy and radiotherapy) the prognosis of patients affected with gliomas is poor and 
it becomes dramatic in patients with glioblastomas. As a matter of fact patients with 
glioblastomas survive less than 1 year and prognosis has not consistently changed over the 
last two decades. Again, the reason of this defeat can be found in the rapidly expanding 
nature of these tumors and their capability of invading the normal brain by active cell 
migration. 
Inflammatory cells are a key component of the tumor microenvironment (Mantovani et al 
2008; Hanahan and Weinberg  2011). Chemokines play an important role in orchestrating 
leukocytes recruitment in tumors including gliomas. Moreover, these molecules affect 
various aspects of tumor cell function (Balkwill et al 2004, Mantovani et al 2006-2008, 
Lazennec and Richmond 2010). Here we will review available information on the expression 
and role of chemokines in gliomas.  
2. The chemokine universe  
Chemokines are a large family of small chemoattractant cytochines. They comprise 
approximately 50 ligands and 20 receptors in humans. The number and position of 
conserved cysteine residues divide this family of related molecules into two major (CXC and 
CC) and two minor (C and CX3C) chemokine classes (Mantovani et al 2006, Charo and 
Ransohoff  2006).  
Chemokine receptors are G-protein coupled, seven transmembrane receptors. Based on the 
chemokine class they bind, the receptors have been named CXCR1-7 (bind to CXC 
chemokines); CCR1 through CCR10 (bound to CC chemokines), XCR1 (bound to the C 
chemokine, lymphotactin/XCL1) and CX3CR1 (bound to the CX3C chemokine, 
fractalkine/CXCL1) (Zlotnik 2006). Another classification is between homeostic and 
inflammatory molecules according to the chemokine constitutive (e.g. SDF1/CXCL12) or 
inflammatory-induced (e.g. CCL2) production, respectively Importantly, if this classification 
is useful it can be criticized because it does not take into account chemokines classified as 
inflammatory that are locally but constitutively expressed by tumor cells or in a tissue 
specific manner (e.g. CX3CL1 in brain).  
The most important targets of chemokines are leukocytes. Their ability to orchestrate 
leucocyte trafficking under basal and inflammatory conditions is generally named as 
chemotaxis, but chemokine control is also exerted on cell adhesion, proliferation, survival 
and gene transcription (Campbell and Butcher 2000). 
Moreover, chemokine action is not only limited to white cells but it extends to many other 
cell populations. In particular, chemokine and chemokine receptors are widely expressed 
into the central nervous system both by neurons and glial cells. The chemokine network in 
the central nervous system is involved in several brain processes such as cell migration, 
regulation of neuronal survival, neurotransmission and cell-cell communication (Ambrosini 
and Aloisi 2004). For this reason chemokine and chemokine receptors can be considered the 
third major transmitter system in the brain (Adler et al 2005). Interestingly, the chemokine 
universe seems to be altered in neurodegenerative disorders such as Alzheimer like 
dementia, multiple sclerosis and brain tumors (Ransohoff et al 2009, Sciumè et al 2010-2011, 
Marchesi et al 2010, Trettel et al 2010). 
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3. Chemokines in gliomas  
3.1 Glioma cell expression of chemokine and chemokine receptors 
The migratory ability of gliomas has been investigated by electron microscopy and it was 
shown that neoplastic cells easily adjust their shape and size to slip through the narrow 
brain spaces, a process that requires Cl channels (Mc Coy and Sontheimer 2007). 
It is now established that migrating malignant cells exploit chemokine receptors to invade 
surrounding tissues thus leading to distant metastasis (Balkwill 2004, Zlotnik 2006, 
Mantovani et al 2010). 
The expression of chemokines and chemokine receptors is considered to play a role in tumor 
cell proliferation, invasion, migration and ability to metastasize. This expression can be 
activated or amplified by both stromal cells and tumor cells themselves (Mantovani et al 
2010).  
Moreover the immune cell infiltration in the neoplastic area largely depends on the 
chemokine expression.  
Since 1990 the production of chemokines by cell lines of glioma has been described (IL-
8/CXCL8; MCP1/CCL2 etc). In particular, CCL2 was described to be expressed in low and 
high grade glioma cells both “in vitro” and “in vivo” (Jiang et al 1990, Kasahara et al 1991, 
Nitta et al 1992, Kuratsu et al 1993). In 1997 Desbaillets and colleagues demonstrated high 
levels of expression of CXCL8 and its receptors CXCR1 and CXCR2 within the  necrotic 
areas surrounding brain tumor cells. Significantly, the presence of these two receptors was 
described in endothelial cells of new blood vessels, suggesting they may be implicated in 
neoangiogenesis. 
At the early 2000s an important role of the CXCR4/CXCL12 axis has been identified for the 
regulation of different aspects of glioma tumor progression. High levels of this complex 
expression were demonstrated in areas nearby tumor necrosis (Rempel et al 2000). CXCR4 
as well as CXCL8 were also demonstrated to be expressed both in glioma cells lines and 
primary glioblastomas. Interestingly, CXCL8 and CXCL12 “in vivo” secretion can also arise 
from other cellular populations such as endothelial cells and macrophage/microglial cells, 
and these populations are  implied in gliomagenesis (Hong et al 2009). The expression of 
CXCL10, CXCL8 and CCL2 is increased by CXCL12-induced CXCR4 stimulation in gliomas 
thus creating a sort of amplification loop which influence tumor growth, angiogenesis and 
immune cells infiltration. 
The increased expression of  IP10/CXCL10 and of CCL3L1 and their receptors found in 
glioma cells compared to “normal” astrocytes lead to hypothesize an autocrine role for these 
axes in glioma control (Maru et al 2008). The high expression of CX3CL1 (or fractalkine) in 
the brain has suggested that also CX3CL1/CX3CR1 axis may play a role in malignancies of 
the central nervous system (Locatelli et al 2010, Marchesi et al 2010, Sciumè et al 2010). 
Indeed, neurons and astrocytes are major producers of the ligand and microglia express the 
receptor CX3CR1 expression has been detected both in glial cells and in neurons. 
Experimental evidence established that this axis play a major role in the neuron/microglia 
cross-talk and in neuroprotection under conditions of inflammation (Cardona et al 2006, 
Gunther et al 2005, Miller et al 2008).  
Using a murine model a positive in situ hybridization for CX3CR1 corresponding with the 
localisation of CD11b-positive microglia was described (Liu et al 2008). As for human 
glioblastomas CX3CR1 immunopositivity was found in neoplastic cells (Ludwig et al 2005, 
Locatelli et al 2010).  
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Moreover, Sciumè and colleagues in 2010 described that glioblastomas cells express both the 
membrane-bound and the secreted form of CX3CL1 and its receptor CX3CR1. Marked 
expression of CX3CR1 was similar across low and high grade tumor though it was highest 
in glioblastomas. The presence of receptor expression in low grade tumor suggests that its 
upregulation is an early event during malignant transformation. In a recent paper (Erreni et 
al 2010) CX3CR1 was similarly detected in low and high grade tumors while the uppermost 
score of CX3CL1 were found in grades II and IV. Accordingly, the expression of fractlakine 
was inversely correlated to the patient survival. 
Notably, constitutive expression of CX3CL1 in CX3CR1 positive glioblastomas negatively 
regulates tumor cell invasiveness by promoting their aggregation (Sciumè et al 2010). 
CX3CL1 is induced by TNF α and TNF β in neurons (Chen et al 2002, Sciumè et al 2010). 
These mediators are frequently present in tumors including gliomas and may be involved in 
the modulation of CX3CL1/CX3CR1 axis in neoplastic conditions (Mantovani et al 2008, 
Balkwill et al 2009).  
In 2005 Ludwig and colleagues demonstrated that another membrane-bound chemokine, 
CXCL16 is upregulated in human glioma being this chemokine expression low in normal 
brain and substantially limited to brain endothelial cells. 
Expression of chemokines and their receptors is modulated by factors produced by gliomas 
or by the tumor microenvironment. Examples are CXCL8, CXCL12 anCXCR4 which are up 
regulated in hypoxic conditions or upon stimulation with VEGF, an angiogenetic growth 
factor expressed in glioma tissues (Desbaillets et al 1997, Zagzag et al 2008). 
3.2 Chemokines in glioma invasion 
The peculiar adhesive function of fractalkine in the nervous system suggests that this 
chemokine/receptor complex plays a role in the neurotropism of cancer cells to peripheral 
nerves. This is a distinct and largely underestimated way of metastasis compared to blood 
and lymphatic routes; many human carcinomas such as bladder, prostate and pancreas take 
advantage of this route (Marchesi et al 2010). 
The invasive process of glioma cells requires the detachment of invading cells from the 
primary mass of the tumor, attachment to extracellular matrix components and degradation 
of this matrix. At this point tumor cell migration into brain structures can take place. 
CX3CL1 would have a negative role in this process, as suggested by the increase in glioma 
cell invasion properties by the blockade  induced by CX3CR1-CX3CL1 axis. Moreover, the 
reduced CX3CR1 expression consequent to TGF-beta 1 activation can favour glioma 
invasiveness (Sciumè et al 2010).  
Another axis which is acquiring an increasing consideration in this complex process is the 
CXCL12/CXCR4 axis. This axis has been linked to glioma progression both “in vitro” and 
“in vivo” (Zhou et al 2002, Zhang et al 2005, Ehtesham et al 2006, Bajetto et al 2006)  because 
of its ability to activate metalloproteinases, including the membrane type-2-MMP. 
Accordingly, invasive human glioma cell overexpress CXCR4 while noninvasive glioma cell 
do not. These data were confirmed “in vivo” in neoplastic cells from a rat C6 glioma cell line 
(Ehtesham et al 2006). 
 Co-expression of CXCL12 and its receptors is mainly localized to the pseudopalisade zones 
that surround necrotic foci (Rempel et al 2000). These regions are believed to represent 
tumor cells which are leaving necrotic regions because of their low or absent oxygen levels. 
In hypoxic condition, tumor cells release an angiogentic growth factor (VEGF) which 
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promotes the over-expression of CXCL12 and consequently tumor invasion outside the 
hypoxic area (Zagzag et al 2008). 
Promotion of glioma cell invasion is also mediated by Gro-alpha/CXCL1 that is expressed 
by oligodendroglioma and anaplastic astrocytomas (Zhou et al 2005). Interestingly CXCL1 
overexpression conferred increased tumorigenicity to U251 cells following implantation into 
the brain of nude mice (Zhou et al 2005). 
3.3 Chemokine role in glioma proliferation 
In addition to CXCL12, also CXCL8, CXCL10 and CCL3L1 have been described to promote 
glioma cell proliferation in vitro (Kouno et al 2004, Maru et al 2008). Notably, a correlation 
between CXCL8 expression levels in cells surrounding necrotic areas and histologic grade in 
glioma has been demonstrated (Desbaillets et al 1997). 
Chemokines also contribute to create a proangiogenic microenvironment by promoting 
attraction of endothelial cells and leukocytes to the tumor. The chemokine receptor panel of 
human microvascular endothelial cells includes CXCR2, CXCR3B, CXCR4 and CX3CR1 
(Bernardini et al 2003). 
As mentioned above, CXCR4 is expressed by both tumor cells and vascular endothelial cells in 
different grades of gliomas; this is associated with CXCL12 production in the tumor 
microenvironment, which is capable  to modulate migration, proliferation and survival of 
endothelial and tumor cells (Salmaggi et 2004). It was demonstrated that CXCR4 is expressed 
by both tumor cells and vascular endothelial cells in all grades of gliomas. The administration 
of AMD-3100, a CXCR4 antagonist, inhibits the growth of glioblastoma xenografts in mouses, 
demonstrating the dependence of tumor cells proliferation on CXCR4 (Rubin et al 2003). 
3.4 Chemokine network and leukocyte infiltration  
Besides its direct effects on tumor growth, the network of chemokines implicated in human 
astrcytomas can influence the degree and phenotype of immune cell infiltration. However,  
it is well accepted that glioma cells can be recognized by both innate and adaptive immunity 
(Mantovani et al 2008, Friese et al 2004, Dunn et al 2007). T-cell infiltration has been 
described to be present in neuroephitelial tumors, on the contrary NK cells are poorly 
included in the glioma lymphocyte infiltrate (Vaquero et al 1989). 
To date, data regarding the specificity and function of  tumor –infiltrating lynphocytes such 
as the involvement of the chemokine network in the recruitment of these cells or tumor 
infiltrating microglia/macrophages are lacking. Glia derived CCL2 might be implicated in 
the process leading to the abundant tumor infiltration by macrophages/microglia and T 
cells (Jordan et al 2008). CCL2 expression by glioma cells would be advantageous for tumor 
progression thanks to the attraction of T regulatory cells that suppress lymphocyte anti 
tumor effector functions and of microglia cells with reduce anti-tumor functions. Another 
effect would be the secretion of metalloproteinases. The corresponding receptors were the 
CCR2 on microglia and CCR4 on T regulatory cells (Hussain et al 2006). The role of the 
CX3CL1/CX3CR1 chemokine/receptor pair in microglial and lymphocyte infiltration 
remains to be defined.(Liu et al 2008, Rodero et al 2008) 
3.5 Concluding remarks 
Available information strongly suggest that chemokines play an important role in gliomas. 
In particular, evidence suggests that they are orchestrators of leukocyte recruitment in the 
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glioma microenvironment. Moreover, glioma cells express a defined repertoire of 
chemokine receptors including CXCR4/CXCL12, CX3CL1/CX3CR1 axis. 
On the basis of available information and extrapolation from other tumors, chemokine 
receptors expressed on gliomas may have a broad impact on biological and clinical 
behaviour of the tumor, affecting different functions including invasion, cell survival and 
proliferation. 
Despite increasing evidence on this complexity, further investigations of this network will 
allow a better understanding of tumor specificities, biological behaviour and therapeutic 
failures. 
These data and considerations raise the possibility of targeting components of the 






Fig. 1. Inflammatory mediators in gliomas. Innate and adaptive immune cells together with 
inflammatory molecules and cancer cells are part of an inflammatory microenvironment 
which may have an impact on biological and clinical behaviour of gliomas. 
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